← Back to Search

Antioxidant

Sulforaphane for Chronic Kidney Disease

Phase 1 & 2

Waitlist Available

Research Sponsored by University of Rochester

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up prior to initial dose on day 7 and 2, 4, and 8 hours post-dose

Awards & highlights

Study Summary

This trial will test if the drug sulforaphane is safe for people with kidney disease by giving it to them in different doses and seeing what levels show up in their blood.

Eligible Conditions

Chronic Kidney Disease
Renal Disease

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ prior to initial dose on day 7 and 2, 4, and 8 hours post-dose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~prior to initial dose on day 7 and 2, 4, and 8 hours post-dose

This trial's timeline: 3 weeks for screening, Varies for treatment, and prior to initial dose on day 7 and 2, 4, and 8 hours post-dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Area Under the Concentration-Time Curve (AUC 0-8h) in serum

Area Under the Concentration-Time Curve (AUC 0-8h) in urine

Number of participants with an adverse event

Side effects data

From 2013 Phase 2 trial • 20 Patients • NCT01228084

35%

Flatulence

35%

Nausea

20%

Bloating

20%

Diarrhea

20%

Dyspepsia

15%

Gatrointestinal pain

100%

80%

60%

40%

20%

Study treatment Arm

Sulpforaphane

Trial Design

3Treatment groups

Experimental Treatment

Group I: 6 tablets of SulforaphaneExperimental Treatment1 Intervention

Participants will be given 6 extra strength tablets per day

Group II: 4 tablets of SulforaphaneExperimental Treatment1 Intervention

Participants will be given 4 extra strength tablets per day

Group III: 2 tablets of SulforaphaneExperimental Treatment1 Intervention

Participants will be given 2 extra strength tablets per day

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Sulforaphane

2016

Completed Phase 3

~550

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of RochesterLead Sponsor

836 Previous Clinical Trials

518,073 Total Patients Enrolled

National Institutes of Health (NIH)NIH

2,696 Previous Clinical Trials

6,952,559 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many willing test subjects are being recruited for this research?

"Correct, the listings on clinicaltrials.gov show that this study is currently looking for 24 participants at a single location. The trial was first posted on May 2nd, 2022 and updated May 13th, 2022."

Answered by AI

Are there still vacancies in this clinical research program?

"Yes, this trial is still looking for individuals to enroll. According to the information on clinicaltrials.gov, the posting date was May 2nd, 2022 and the most recent edit was done on May 13th of the same year."

Answered by AI

Does this research include elderly patients in its testing?

"The age range for this study is 18 to 80, which sets it apart from the 44 trials conducted for minors and 480 studies focused on senior citizens."

Answered by AI

Who meets the eligibility requirements for participating in this research study?

"Up to 24 patients with renal impairment will be enrolled in this study. Key inclusion criteria are as follows: eGFR ≥ 20 and <60 ml/min/m2/year, evidence of declining renal function (eGFR decline of ≥ 3 ml/min/m2/year) in the last 12 months, capacity to provide informed consent, ability to swallow capsules."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of Sulphoraphane in Chronic Kidney Disease

Thu Le 2022. "Study of Sulphoraphane in Chronic Kidney Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05153174.